Kristen Fortney, BioAge Labs CEO
September 3, 2024 09:37 PM EDTUpdated 08:08 AM
Financing
R&D

BioAge files for IPO, rid­ing mo­men­tum for weight loss drugs

Max Bayer

Pharma Reporter

BioAge Labs is head­ing to Wall Street af­ter months of spec­u­la­tion that the Eli Lil­ly-part­nered car­diometa­bol­ic biotech was plan­ning to join the pub­lic mar­kets. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times